Melanocortin-4 receptor antagonists for the treatment of depression and anxiety disorders

Current Topics in Medicinal Chemistry

Volumn 7, Issue 11, 2007, Pages 1145-1151

  Chaki, Shigeyuki ^a   Okubo, Taketoshi ^a  

^a TAISHO PHARMACEUTICAL CO LTD   (Japan)

Author keywords

Antidepressant; Anxiety; Anxiolytic; Depression; Hypothalamus pituitary adrenal axis; MC4 receptor; Melanocortin

Indexed keywords

1 [2 (4 FLUOROPHENYL) 2 (4 ISOPROPYLPIPERADIN 1 YL)ETHYL] 4 [4 [2 METHOXYNAPHTHALEN 1 YL]BUTYL]PIPERAZINE; 1 [2 (4 FLUOROPHENYL) 2 (4 METHYLPIPERAZIN 1 YL)ETHYL] 4 [4 [1 NAPHATHYL]BUTYL]PIPERAZINE; ACETYL DEXTRO 2 NAPHTHYLALANYLARGINYL 2 NAPHTHYLALANYLAMIDE; ALPHA INTERMEDIN DERIVATIVE; AMIDE; BETA INTERMEDIN[11-22][11 (N ACETYLCYSTEINE) 14 [3 (2 NAPHTHYL) DEXTRO ALANINE] 18 CYSTEINE 22 ASPARTIC ACID AMIDE] 11,18 CYCLIC DISULFIDE; CLONAZEPAM; CYCLIC AMP; G PROTEIN COUPLED RECEPTOR; HORMONE RECEPTOR BLOCKING AGENT; MCL 0020; MCL 0042; MCL 0129; MELANOCORTIN; MELANOCORTIN 1 RECEPTOR; MELANOCORTIN 2 RECEPTOR; MELANOCORTIN 3 RECEPTOR; MELANOCORTIN 4 RECEPTOR; MELANOCORTIN 4 RECEPTOR ANTAGONIST; MELANOCORTIN 5 RECEPTOR; MELANOTAN II; N ACETYL ALPHA INTERMEDIN[4-10]CYCLO[4 NORLEUCINE 5 ASPARTIC ACID 7 [3 (2 NAPHTHYL)ALANINE] 10 LYSINAMIDE]; PIPERAZINE DERIVATIVE; PROOPIOMELANOCORTIN; RECEPTOR SUBTYPE; SEROTONIN UPTAKE INHIBITOR; UNCLASSIFIED DRUG;

ANXIETY; ANXIETY DISORDER; BEHAVIOR; CELL SURFACE; CENTRAL NERVOUS SYSTEM; DEPRESSION; DRUG STRUCTURE; EMOTION; HORMONE RECEPTOR INTERACTION; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; NONHUMAN; PROTEIN DEGRADATION; PROTEIN EXPRESSION; REGULATORY MECHANISM; REVIEW; RODENT; STRESS; TRANQUILIZING ACTIVITY;

ANIMALS; ANXIETY DISORDERS; BRAIN; DEPRESSION; HUMANS; RECEPTOR, MELANOCORTIN, TYPE 4; STRESS;

EID: 34447261891     PISSN: 15680266     EISSN: None     Source Type: Journal    
DOI: 10.2174/156802607780906618     Document Type: Review

References (69)

1. Fan, W.; Boston, B.A.; Kesterson, R.A.; Hruby, V.J.; Cone, R.D. Role of melanocortinergic neurons in feeding and the agouti obesity syndrome. Nature 1997, 385, 165-168.
2. Seeley, R.J.; Drazen, D.L.; Clegg, D.J. The critical role of The melanocortin system in the control of energy balance. Annu. Rev. Nutr. 2004, 24, 133-149.
3. Murphy, M.T.; Richards, D.B.; Lipton, J.M. Antipyretic potency of centrally administered alpha-melanocyte stimulating hormone. Science 1983, 221, 192-193.
4. Vrinten, D.H.; Gispen, W.H.; Groen, G.J.; Adan, R.A. Antagonism of the melanocortin system reduces cold and mechanical allodynia in mononeuropathic rats. J. Neurosci. 2000, 20, 8131-8137.
5. Ceriani, G.; Macaluso, A.; Catania, A.; Lipton, J.M. Central neurogenic antiinflammatory action of alpha-MSH: modulation of peripheral inflammation induced by cytokines and other mediators of inflammation. Neuroendocrinology 1994, 59, 138-143.
6. Thody, A.J. alpha-MSH and the regulation of melanocyte function. Ann. N.Y. Acad. Sci. 1999, 885, 217-229.
7. Gee, C.E.; Chen, C.L.; Roberts, J.L.; Thompson, R.; Watson, S.J. Identification of proopiomelanocortin neurones in rat hypothalamus by in situ cDNA-mRNA hybridization. Nature 1993, 306, 374-376.
8. Bagnol, D.; Lu, X.Y.; Kaelin, C.B.; Day, H.E.; Ollmann M.; Gantz, I.; Akil, H.; Barsh, G.S.; Watson, S.J. Anatomy of an endogenous antagonist, relationship between Agouti-related protein and proopiomelanocortin in brain. J. Neurosci. 1999, 19, RC26 1-7.
9. Kiss, J.Z.; Cassell, M.D.; Palkovits, M. Analysis of the ACTH/beta-End/ alpha-MSH-immunoreactive afferent input to the hypothalamic paraventricular nucleus of rat. Brain Res. 1984, 324, 91-99.
10. Gray, T.S.; Cassell, M.D.; Kiss, J.Z. Distribution of pro-opiomelanocortin-derived peptides and enkephalins in the rat central nucleus of the amygdala. Brain Res. 1984, 306, 354-358.
11. Lu, D.; Willard, D.; Patel, I.R.; Kadwell, S.; Overton, L.; Kost, T.; Luther, M.; Chen, W.; Woychik, R.P.; Wilkison, W.O.; Cone, R.D. Agouti protein is an antagonist of the melanocyte-stimulating-hormone receptor. Nature 1994, 371, 799-802.
12. Ollmann, M.M.; Wilson, B.D.; Yang, Y.K.; Kerns, J.A.; Chen, Y.; Gantz, I.; Barsh, G.S. Antagonism of central melanocortin receptors in vitro and in vivo by agouti-related protein. Science 1997, 278, 135-138.
13. Wikberg, J.E. Melanocortin receptors: perspectives for novel drugs. Eur. J. Pharmacol. 1999, 375, 295-310.
14. Mountjoy, K.G.; Robbins, L.S.; Mortrud, M.T.; Cone, R.D. The cloning of a family of genes that encode the melanocortin receptors. Science 1992, 257, 1248-1251.
15. Gantz, I.; Konda, Y.; Tashiro, T.; Shimoto, Y.; Miwa, H.; Munzert, G.; Watson, S.J.; DelValle, J.; Yamada, T. Molecular cloning of a novel melanocortin receptor. J. Biol. Chem. 1993, 268, 8246-8250.
16. Catania, A.; Gatti, S.; Colombo, G.; Lipton, J.M. Targeting melanocortin receptors as a novel strategy to control inflammation. Pharmacol. Rev. 2004, 56, 1-29.
17. Roselli-Rehfuss, L.; Mountjoy, K.G.; Robbins, L.S.; Mortrud, M.T.; Low, M.L; Tatro, J.B.; Entwistle, M.L.; Simerly, R.B.; Cone, R.D. Identification of a receptor for gamma melanotropin and other proopiomelanocortin peptides in the hypothalamus and limbic system. Proc. Natl. Acad. Sci. USA 1993, 90, 8856-8860.
18. Butler, A.A.; Kesterson, R.A.; Khong, K,; Cullen, M.J.; Pelleymounter, M.A.; Dekoning, J.; Baetscher, M.; Cone, R.D. A unique metabolic syndrome causes obesity in die melanocortin-3 receptor-deficient mouse. Endocrinology 2000, 141, 3518-3521.
19. Gantz, I.; Miwa, H.; Konda, Y.; Shimoto, Y.; Tashiro, T.; Watson, S.J.; DelValle, J.; Yamada, T. Molecular cloning, expression, and gene localization of a fourth melanocortin receptor. J. Biol. Chem. 1993, 268, 15174-15179.
20. Alvaro, J.D.; Tatro, J.B.; Quillan, J.M.; Fogliano, M.; Eisenhard, M.; Lerner, M.R.; Nestler, E.J.; Duman, R.S. Morphine down-regulates melanocortin-4 receptor expression in brain regions that mediate opiate addiction. Mol. Pharmacol. 1996, 50, 583-591.
21. Kishi. T.; Aschkenasi, C.J.; Lee, C.E.; Mountjoy, K.G.; Saper, C.B.; Elmquist, J.K. Expression of melanocortin 4 receptor mRNA in the central nervous system of the rat. J. Comp. Neurol. 2003, 457, 213-235.
22. Mountjoy, K.G.; Mortrud, M.T.; Low, M.J.; Simerly, R.B.; Cone, R.D. Localization of die melanocortin-4 receptor (MC4-R) in neuroendocrine and autonomic control circuits in the brain. Mol. Endocrinol. 1994, 8, 1298-1308.
23. Chhajlani, V. Distribution of cDNA for melanocortin receptor subtypes in human tissues. Biochem. Mol. Biol. Int. 1996, 38, 73-80.
24. Kawashima, N.; Chaki, S.; Okuyama, S. Electrophysiological effects of melanocortin receptor ligands on neuronal activities of monoaminergic neurons in rats. Neurosci. Lett. 2003, 353, 119-122.
25. Adan, R.A.; Szklarczyk, A.W.; Oosterom, J.; Brakkee, J.H.; Nijenhuis, W.A.; Schaaper, W.M.; Meloen, R.H.; Gispen, W.H. Characterization of melanocortin receptor ligands on cloned brain metanocortin receptors and on grooming behavior in the rat. Eur. J. Pharmacol. 1999, 378, 249-258.
26. De Barioglio, S.R.; Lezcano, N.; Celia, M.E. Alpha MSH-induced excessive grooming behavior involves a GABAergic mechanism. Peptides 1991, 12, 203-205.
27. Dunn, A.J.; Green, E.J.; Isaacson, R.L. Intracerebral adrenocorticotropic hormone mediates novelty-induced grooming in the rat. Science 1979, 203, 281-293.
28. Vergoni, A.V.; Bertolini, A.; Wikberg, J.E.; Schioth, H.B. Selective melanocortin MC4 receptor blockage reduces immobilization stress-induced anorexia in rats. Eur. J. Pharmacol. 1999, 369, 11-15.
29. Chaki, S.; Ogawa, S.; Toda, Y.; Funakoshi, T.; Okuyama, S. Involvement of the melanocortin MC4 receptor in stress-related behavior in rodents. Eur. J. Phamacol. 2003, 474, 95-101.
30. Holsboer, F.; Von Bardeleben, U.; Gerken, A.; Stalla, G.K.; Muller, O.A. Blunted corticotropin and normal cortisol response to human corticotropin-releasing factor in depression. N. Engl. J. Med. 1984, 311, 1127-1133.
31. Taylor, A.L.; Fishman, L.M. Corticotropin-releasing hormone. N. Engl. J. Med. 1988, 319, 213-222.
32. Von Frijtag, J.C.; Croiset G.; Gispen, W.H.; Adan, R.A.; Wiegant, V.M. The role of central melanocortin recepturs in the activation of the hypothalamus-pituitary-adrenal-axis and the induction of excessive grooming. Br. J. Pharmacol. 1998, 123, 1503-1508.
33. Lu, X.Y.; Barsh, G.S.; Akil, H.; Watson, S.J. Interaction between alpha-melanocyte-stimulating hormone and corticotropin-releasing hormone in the regulation of feeding and hypethalamo-pituitary-adrenal responses. J. Neurosci. 2003, 23, 7863-7872.
34. Dhillo, W.S.; Small, C.J.; Seal, L.J.; Kim, M.S.; Stanley, S.A.; Murphy, K.G.; Ghatei, M.A.; Bloom, S.R. The hypothalamic melanocortin system stimulates the hypothalamo-pituitary-adrenal axis in vitro and in vivo in male rats. Neuroendocrinology 2002, 75, 209-216.
35. Rivier, C.L.; Plotsky, P.M. Mediation by corticotropin releasing factor (CRF) of adenohypophysial hormone secretion. Annu. Rev. Physiol. 1986, 48, 475-494.
36. Vecsernyes, M.; Biro, E.; Gardi, J.; Julesz, J.; Telegdy, G. Involvement of endogenous corticotropin-releasing factor in mediation of neuroendocrine and behavioral effects to alpha-melanocyte-stimulating hormone. Endocr. Res. 2000, 26, 347-356.
37. Liposits, Z.; Sievers, L.; Paull, W.K. Neuropeptide-Y and ACTH-immunoreactive innervation of corticotropin releasing factor (CRF)-synthesizing neurons in the hypothalamus of the rat. An immunocytochemical analysis at the light and electron microscopic levels. Histochemistry 1988, 88, 227-234.
38. Liu, H.; Kishi, T.; Roseberry, A.G.; Cai, X.; Lee, C.E.; Montez, J.M.; Friedman, J.M.; Elmquist, J.K. Transgenic mice expressing green fluorescent protein under the control of the melanocortin-4 receptor promoter. J. Neurosci. 2003, 23, 7143-7154.
39. Sarkar, S.; Legradi, G.; Lechan, R.M. Intracerebroventricular administration of alpha-melanocyte stimulating hormone increases phosphorylation of CREB in TRH- and CRH-pruducing neurons of the hypothalamic paraventricular nucleus. Brain Res. 2002, 945, 50-59.
40. Aguilera, G.; Rabadan-Diehl, C. Vasopressinergic regulation of the hypothalamic-pituitary-adrenal axis: implications for stress adaptation. Regul. Pept. 2000, 96, 23-29.
41. Larsen, P.J.; Mau, S.E. Effect of acute stress on the expression of hypothalamic messenger ribonucleic acids encoding the endogenous opioid precursors preproenkephalin A and proopiomelanocortin. Peptides 1994, 15, 783-790.
42. Makino, S.; Asaba, K.; Nishiyama, M.; Hashimoto, K. Decreased type 2 corticotropin-releasing hormone receptor mRNA expression in the ventromedial hypothalamus during repeated immobilization stress. Neuroendocrinology 1999, 70, 160-167.
43. Yamano, Y.; Yoshioka, M.; Toda, Y.; Oshida, Y.; Chaki, S.; Hamamoto, K.; Morishima, I. Regulation of CRF, POMC and MC4R gene expression after electrical foot shock stress in the rat amygdala and hypothalamus. J. Vet. Med. Sci. 2004, 66, 1323-1327.
44. Meyer, J.S.; Micco, D.J.; Stephenson, B.S.; Krey, L.C.; McEwen, B.S. Subcutaneous implantation method for chronic glucocorticoid replacement therapy. Physiol. Behav. 1979, 22, 867-870.
45. Ozawa, H.; Lion, J.; Xie, C.X.; Nishi, M.; Steinbusch, H.; Kawata, M. Down-regulation of ACTH and glucocorticoid receptor immunoreactivity in hypothalamic arcuate neurons after adrenalectomy in the rat. Neuroreport 1999, 10, 1571-1575.
46. Davis, M.; Shi, C. The extended amygdala: are the central nucleus of the amygdala and the bed nucleus of the stria terminalis differentially involved in fear versus anxiety? Ann. N.Y. Acad, Sci. 1999, 877, 281-291.
47. Kokare, D.M.; Dandekar, M.P.; Chopde, C.T.; Subhedar, N. Interaction between neuropeptide Y and alpha-melanocyte stimulating hormone in amygdala regulates anxiety in rats. Brain Res. 2005, 1043, 107-114.
48. Panksepp, J.; Abbott, B.B. Modulation of separation distress by alpha-MSH. Peptides 1990, 11, 647-653.
49. Panksepp, J.; Normansell, L. Effects of ACTH(1-24) and ACTH/MSH(4-10) on isolation-induced distress vocalization in domestic chicks. Peptides 1990, 11, 915-919.
50. Corda, M.G.; Orlandi, M.; Fratta, W. Proconflict effect of ACTH1-24: interaction with benzodiazepines. Pharmacol. Biochem. Behav. 1990, 36, 631-634.
51. Shimazaki, T.; Chaki, S. Anxiolytic-like effect of a selective and non-peptidergic melanocortin 4 receptor antagonist, MCL0129, in a social interaction test. Pharmacol. Biochem. Behav. 2005, 80, 395-400.
52. Gonzalez, M.I.; Vaziri, S.; Wilson, C.A. Behavioral effects of alpha-MSH and MCH after central administration in the female rat. Peptides 1996, 17, 171-177.
53. Clarke, A.; File, S.E. Social and exploratory behaviour in the rat after septal administration of ORG 2766 and ACTH4-10. Psychoneuroendocrinology 1983, 8, 343-350.
54. Rao, T.L.; Kokare, D.M.; Sarkar, S.; Khisti, R.T.; Chopde, C.T.; Subhedar, N. GABAergic agents prevent alpha-melanocyte stimulating hormone induced anxiety and anorexia in rats. Pharmacol. Biochem. Behav. 2003, 76, 417-423.
55. Blasquez, C.; Jegou, S.; Tranchand Bunel, D.; Delbende, C.; Braquet, P.; Vaudry, H. Central-type benzodiazepines inhibit release of alpha-melanocyte-stimulating hormone from the rat hypothalamus. Neuroscience 1991, 42, 509-516.
56. Chaki, S.; Hirota, S.; Funakoshi, T.; Suzuki, Y.; Suetake, S.; Okubo, T.; Ishii, T.; Nakazato, A.; Okuyama, S. Anxiolytic-like and antidepressant-like activities of MCL0129 (1-[(S)-2-(4-fluorophenyl)-2-(4-isopropylpiperadin-1-yl)ethyl]-4-[4- (2-methoxynaphthalen-1-yl)butyl]piperazine), a novel and potent nonpeptide antagonist of the melanocortin-4 receptor. J. Pharmacol. Exp. Ther. 2003, 304, 818-826.
57. Chaki, S.; Oshida, Y.; Ogawa, S.; Funakoshi, T.; Shimazaki, T.; Okubo, T.; Nakazato, A.; Okuyama, S. MCL0042: a nonpeptidic MC4 receptor antagonist and serotonin reuptake inhibitor with anxiolytic- and antidepressant-like activity. Pharmacol. Biochem. Behav. 2005, 82, 621-626
58. Cryan, J.F.; Markou, A.; Lucki, I. Assessing antidepressant activity in rodents: recent developments and future needs. Trends Pharmacol. Sci. 2002, 23, 238-245.
59. Zheng, Z.; Leger, L.; Cespuglio, R.; Jouvet, M. Distribution of the proopiomelanocortin-immunoreactive axons in relation to the serotoninergic neurons in the dorsal raphe nucleus of the rat. Neurosci. Lett. 1991, 130, 17-21.
60. Takamori, K.; Yoshida, S.; Okuyama, S. Repeated treatment with imipramine, fluvoxamine and tranylcypromine decreases the number of escape failures by activating dopaminergic systems in a rat learned helplessness test. Life Sci. 2001, 69, 1919-1926.
61. Chaki, S.; Nakazato, A.; Kennis, L.; Nakamura, M.; Mackie, C.; Sugiura, M.; Vinken, P.; Ashton, D.; Langlois, X.; Steckler, T. Anxiolytic- and antidepressant-like profile of a new CRF1 receptor antagonist, R278995/ CRA0450. Eur. J. Pharmacol. 2004, 485, 145-158.
62. Takamori, K.; Kawashima, N.; Chaki, S.; Nakazato, A.; Kameo, K. Involvement of corticotropin-releasing factor subtype 1 receptor in the acquisition phase of learned helplessness in rats. Life Sci. 2001, 69, 1241-1248.
63. Okuyama, S.; Chaki, S.; Kawashima, N.; Suzuki, Y.; Ogawa, S.; Nakazato, A.; Kumagai, T.; Okubo, T.; Tomisawa, K. Receptor binding, behavioral, and electrophysiological profiles of nonpeptide corticotropin-releasing factor subtype 1 receptor antagonists. CRA1000 and CRA1001. J. Pharmacol. Exp. Ther. 1999, 289, 926-935.
64. Griebel, G.; Simiand, J.; Serradeil-Le Gal, C.; Wagnon, J.; Pascal, M.; Scatton, B.; Maffrand, J.P.; Soubrie, P. Anxiolytic- and antidepressant-like effects of the non-peptide vasopressin V1b receptor antagonist, SSR149415, suggest an innovative approach for the treatment of stress-related disorders. Proc. Natl. Acad. Sci. USA 2002, 99, 6370-6375.
65. File, S.E.; Seth, P. A review of 25 years of the social interaction test. Eur. J. Pharmacol. 2003, 463, 35-53.
66. Millan, M.J.; Brocco, M.; Gobert, A.; Dorey, G.; Casara, P.; Dekeyne, A. Anxiolytic properties of the selective, non-peptidergic CRF(1) antagonists, CP154,526 and DMP695: a comparison to other classes of anxiolytic agent. Neuropsychopharmacology 2001, 25, 585-600.
67. Borsini, F.; Podhorna, J.; Marazziti, D. Do animal models of anxiety predict anxiolytic-like effects of antidepressants? Psychopharmacology (Berl) 2002, 163, 121-141.
68. Njung'e, K.; Handley, S.L. Effects of 5-HT uptake inhibitors, agonists and antagonists on the burying of harmless objects by mice; a putative test for anxiolytic agents. Br. J. Pharmacol. 1991, 104, 105-112.
69. Pigott, T.A.; Seay, S.M. A review of the efficacy of selective serotonin reuptake inhibitors in obsessive-compulsive disorder. J. Clin. Psychiatry 1999, 60, 101-106.